CAMP4 Therapeutics Corporation (NASDAQ: CAMP) is a Healthcare company (Biotechnology) with a market capitalization of $251M. The Maz Rating grades it against the other companies in its sector.
CAMP4 Therapeutics Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.00, CAMP4 Therapeutics Corporation trades at 47.2x sales and 2.9x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $129M. It runs a gross margin of 80.4%, an operating margin of -1001.1% and a net margin of -2276.3%. It shows return on equity of -261.8%, return on invested capital of -46.0% and a free cash flow yield of -10.5%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 6.42. Over the past 52 weeks the share price ranged from $2.90 to $7.75, with a beta of 0.21.
CAMP4 Therapeutics Corporation does not currently pay a dividend.
24 Wall Street analyst ratings cover the stock: 16 Buy, 7 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, CAMP4 Therapeutics Corporation (CAMP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 50.8% / 30% · Interest income / Revenue 51.8% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 50.8% / 33% · Receivables / Mkt Cap (36m) 0.09% / 49% · Interest income / Revenue 51.8% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 50.8% / 33.33% · Receivables / Mkt Cap (24m) 0.09% / 33.33% · Interest income / Revenue 51.8% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.71% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.3% / 33.33% · Receivables / Avg Assets (4Q) 0.13% / 33.33% · Interest income / Revenue 51.8% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 92.9% / 33.33% · (Cash+Recv) / Total Assets 93.1% / 33.33% · Interest income / Revenue 51.8% / 5% | Fail |
No. As of September 2026, CAMP4 Therapeutics Corporation (CAMP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. CAMP4 Therapeutics Corporation is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 51.8% of each dividend: CAMP4 Therapeutics Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.